Infectious Diseases

Antibiotics, antifungals, antivirals and other infectious disease pharmaceuticals account for a multibillion sector. The battle against contagious diseases takes places in a highly changeable environment, with a wealth of commercial opportunities arising from quickly emerging threats (e.g. avian flu) and the infectious disease and vaccination policies of national governments and international healthcare organisations. Keep track of the latest industry news and activity with the publications listed under Research and Markets’ Infectious Diseases category.

Our reports, books, and subscriptions will allow you to explore licensing, patents, forecasts, market trends, clinical trials, and drug pipelines. Leading players featured in our publications include Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Johnson & Johnson, Merck, Abbott, GlaxoSmithKline, Lilly, and more.

For publications about Infectious Disease Testing please visit the relevant category under Healthcare and Medical Devices. Show Less ... more

• Pertussis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 70
  Pertussis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Pertussis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Relapsed Multiple Myeloma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 222
  Relapsed Multiple Myeloma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Relapsed Multiple Myeloma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• H1N1 Infection - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 178
  H1N1 Infection – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'H1N1 Infection - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 171
  Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Cancer Pain - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 139
  Cancer Pain – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cancer Pain - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Macular Edema - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 59
  Macular Edema – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Macular Edema - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 439
  Glioblastoma Multiforme (GBM) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 355
  Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Peritoneal Tumor - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 94
  Peritoneal Tumor – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Peritoneal Tumor - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Growth Hormone Deficiency - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 91
  Growth Hormone Deficiency – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Growth Hormone Deficiency - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Transplantation - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 203
  Transplantation – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Transplantation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Gastrointestinal Tract Cancer - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 699
  Gastrointestinal Tract Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gastrointestinal Tract Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Ocular Hypertension - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 105
  Ocular Hypertension – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Ocular Hypertension - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Genital Herpes Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 85
  Genital Herpes Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial...

• Herpes Labialis (Oral Herpes) Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 79
  Herpes Labialis (Oral Herpes) Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Herpes Labialis (Oral Herpes) Global Clinical Trials Review, H1, 2013" provides data on the...

• Helminthiasis Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 64
  Helminthiasis Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Helminthiasis Global Clinical Trials Review, H1, 2013" provides data on the Helminthiasis clinical trial scenario....

• Cellulitis Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 113
  Cellulitis Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Cellulitis Global Clinical Trials Review, H1, 2013" provides data on the Cellulitis clinical trial scenario....

• Mycobacterium Infections Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 105
  Mycobacterium Infections Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Mycobacterium Infections Global Clinical Trials Review, H1, 2013" provides data on the Mycobacterium...

• Malaria Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 120
  Malaria Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Malaria Global Clinical Trials Review, H1, 2013" provides data on the Malaria clinical trial scenario This report...

• Vulvovaginal Candidiasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 50
  Vulvovaginal Candidiasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Vulvovaginal Candidiasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Chikungunya - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 40
  Chikungunya – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chikungunya - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Fever - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 41
  Fever – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Fever - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Genital Herpes - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 56
  Genital Herpes – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Genital Herpes - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 66
  Varicella Zoster (HHV-3) Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 80
  Global Markets Direct's, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information...

• Urinary Tract Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 113
  Urinary Tract Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Urinary Tract Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 124
  Cytomegalovirus (HHV-5) Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 151
  Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013', provides an overview...

• Rotavirus Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 46
  Rotavirus Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Rotavirus Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Hepatitis C - Pipeline Review, H1 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Feb 2013 , Pages: 257
  Hepatitis C – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Hepatitis C - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Helicobacter Pylori Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 69
  Helicobacter Pylori Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Helicobacter Pylori Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Seasonal Influenza - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 87
  Seasonal Influenza – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Seasonal Influenza - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 62
  Ventilator Associated Pneumonia (VAP) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Clostridium Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 134
  Clostridium Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 48
  Complicated Skin And Skin Structure Infections (cSSSI) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2013',...

• Pneumonia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 160
  Pneumonia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Pneumonia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Pyelonephritis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 42
  Pyelonephritis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Pyelonephritis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Herpes Zoster (Shingles) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 48
  Herpes Zoster (Shingles) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Herpes Zoster (Shingles) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Aspergillosis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 44
  Aspergillosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Aspergillosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Tuberculosis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 245
  Tuberculosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Tuberculosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Competing in the Global Sexually-Transmitted Disease Testing Market: Emerging Tests, Technology Assessment, Instrumentation Review, Market Shares, Sales Forecasts by Country, Strategic Profiles of Key Players

  EURO€ 7,379.00USD$ 9,600.00GBP£ 6,208.00AUD$ 9,390.00JPY¥ 947,837.00SEK 63 032,00CHF 9'048.00CAD$ 9,782.00 Venture Planning Group (VPG), Feb 2013 , Pages: 350
  This new 350-page report from Venture Planning Group contains 90 tables and provides analysis of the global sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation,...

• Competing in the Japanese Infectious Disease Testing Market

  EURO€ 6,764.00USD$ 8,800.00GBP£ 5,691.00AUD$ 8,607.00JPY¥ 868,850.00SEK 57 779,00CHF 8'294.00CAD$ 8,967.00 Venture Planning Group (VPG), Feb 2013 , Pages: 976
  This new 976-page report from Venture Plannin Group contains 160 tables, and presents a comprehensive analysis of the Japanese infectious disease testing market, including: - Major issues pertaining...

• Competing in the US Infectious Disease Testing Market

  EURO€ 7,571.00USD$ 9,850.00GBP£ 6,370.00AUD$ 9,634.00JPY¥ 972,520.00SEK 64 674,00CHF 9'284.00CAD$ 10,037.00 Venture Planning Group (VPG), Feb 2013 , Pages: 1037
  This new 1,037-page report from Venture Planning Group contains 177 tables, and presents a comprehensive analysis of the US infectious disease testing market, including: - Major issues pertaining to...

• Endotoxemia Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 47
  Endotoxemia Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Endotoxemia Global Clinical Trials Review, H1, 2013" provides data on the Endotoxemia clinical trial scenario....

• Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 87
  Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2013" provides...

• Competing in the Global Infectious Disease Testing Market

  EURO€ 24,981.00USD$ 32,500.00GBP£ 21,017.00AUD$ 31,787.00JPY¥ 3,208,822.00SEK 213 390,00CHF 30'632.00CAD$ 33,117.00 Venture Planning Group (VPG), Feb 2013 , Pages: 1900
  The new report from Venture Planning Group contains 1,900 pages, 820 tables and provides market segmentation analysis of over 100 diseases and viruses in seven countries, assessment of emerging technologies,...

• Quad 2 (HIV) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Jan 2013 , Pages: 55
  Quad 2 (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quad 2 (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency...

• Complera (HIV) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Jan 2013 , Pages: 41
  Complera (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Complera (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency...

• 572-Trii (HIV) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Jan 2013 , Pages: 57
  572-Trii (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “572-Trii (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency...

• Cobicistat (HIV) - Forecast and Market Analysis to 2022

  EURO€ 2,686.00USD$ 3,495.00GBP£ 2,260.00AUD$ 3,418.00JPY¥ 345,072.00SEK 22 948,00CHF 3'294.00CAD$ 3,561.00 GlobalData, Jan 2013 , Pages: 55
  Cobicistat (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cobicistat (HIV) - Forecast and Market Analysis to 2022”. Human...